Industry

Unlocking the hidden world of the small intestine: a new frontier in microbiome science

Cmbio announces a strategic partnership with Nimble Science to deliver first in class high-quality, multi-omic data insights from the small intestine.

Cmbio® strengthens its digital biology platform with acquisition of Eagle Genomics’ assets

The acquisition will enhance its ability to address the needs of a growing market, empowering researchers and industries worldwide.

Revolutionizing treatment for Acute Graft-versus-Host Disease: MaaT Pharma’s groundbreaking Phase 3 results

The live biotherapeutics market is forecasted to exceed $4 billion by 2030, driven by advancements like MaaT013.

Gut to lung: how a new Akkermansia muciniphila strain is reshaping respiratory health

Its emergence in the respiratory health sector represents a paradigm shift, offering promising avenues for innovation and investment.

Microbio’s MS-20 shows breakthrough potential in enhancing Keytruda for advanced lung cancer

The study revealed that MS-20 dramatically improved treatment outcomes, tripling the objective response rate (ORR) to 75% when combined with Keytruda.

MaaT Pharma reports positive Phase 1b results for MaaT033 in ALS, setting the stage for future advances

A significant milestone for both microbiome research and neurodegenerative diseases.

Freya Biosciences secures $10.4 million investment to tackle women’s health challenges

A Bill & Melinda Gates Foundation strategic investment to tackle bacterial vaginosis and improve maternal and neonatal health outcomes worldwide.

From Biofarma Group a probiotic therapy as an adjuvant to cancer immunotherapy

Biofarma Group has launched an innovative project in collaboration with the Department of Surgery, Endocrinology and Gastroenterology of the University of Naples ‘Federico II’, the Centro Sperimentale del Latte (CSL)…

QIAGEN and McGill University partner to drive innovation in microbiome research

Three-year collaboration to pioneer new insights in microbial sciences and health applications.

EnteroBiotix’s EBX-102 shows promising Phase 1b results for liver cirrhosis treatment

New microbiome based therapy demonstrates safety and potential benefits for liver cirrhosis and mental health.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top